Updated on:
This article has been updated to reflect the FDA’s finalization of its biosimilar comparative analytical assessment guidance (September 2025); expanded coverage of higher-order structure analysis methods, including HDX-MS and cryo-EM; and current ICH Q6B framework requirements for biopharmaceutical submissions.
Protein characterization is the systematic analytical process of determining the physical, chemical, and biological properties of a protein. For biology and life sciences applications (biopharmaceuticals, biologics, and research proteins alike), it encompasses identity confirmation, purity assessment, structural analysis, and functional evaluation. Method selection is driven by the characterization objective, the regulatory submission context, and the complexity of the molecule: whether a small recombinant peptide or a full-size monoclonal antibody (mAb).
Key Takeaways
- Protein characterization encompasses physicochemical, structural, and biological property assessment across primary, secondary, tertiary, and quaternary levels of protein organization.
- ICH Q6B defines the regulatory framework for characterization of biopharmaceutical proteins and polypeptides submitted in marketing applications to the FDA, EMA, and other major agencies.
- Method selection depends on the characterization objective: identity, purity, potency, higher-order structure, or post-translational modification (PTM) profiling.
- Biosimilar development demands orthogonal analytical strategies across multiple independent techniques to establish analytical similarity with a reference product.
- Contract laboratories with GMP, GLP, and ICH Q6B compliance offer specialized instrumentation, validated methods, and regulatory-ready data packages.
Why Protein Characterization Is a Regulatory Imperative
Regulatory agencies require comprehensive protein characterization before any biopharmaceutical product can advance through development or enter the market. ICH Q6B, issued by the International Council for Harmonisation and adopted by FDA’s CDER and CBER, establishes the foundational specifications framework: test procedures and acceptance criteria covering physicochemical properties, biological activity, immunochemical properties, purity, and impurity profiles. It applies to proteins and polypeptides produced from recombinant or non-recombinant cell-culture expression systems.
For biosimilar development, the FDA finalized its Development of Therapeutic Protein Biosimilars: Comparative Analytical Assessment and Other Quality-Related Considerations guidance in September 2025, replacing the 2019 draft. That guidance governs how sponsors design and evaluate comparative analytical studies to support a demonstration of biosimilarity under section 351(k) of the Public Health Service Act. It reinforces the expectation of orthogonal analytical strategies, meaning no single technique is sufficient; multiple independent methods must converge on the same conclusion to satisfy the agency.
Failing to characterize a protein thoroughly introduces risk at every stage: failed batch releases, clinical holds, IND/BLA rejection, and post-market safety signals tied to immunogenicity from process-related impurities such as host cell proteins (HCPs).
Protein Purification: The Prerequisite Step
Before characterization can begin, the protein must be isolated from the expression system. Isolation strategy depends on the molecule’s size, charge, hydrophobicity, and binding affinity. The three primary purification techniques are centrifugation (separation by mass and density), electrophoresis (separation by charge-to-mass ratio), and chromatography (separation by mass, charge, or binding affinity).
Chromatography is the dominant industrial purification platform. Affinity chromatography, particularly protein A chromatography for mAbs, delivers high selectivity in a single step. Ion exchange chromatography (IEX) resolves charge variants, while size exclusion chromatography (SEC) separates aggregates and fragments from the monomeric protein. The choice of purification sequence directly determines the impurity profile and, by extension, which characterization assays are needed downstream.
Primary Structure Analysis: Sequence and Modification Mapping
Primary structure characterization confirms the amino acid sequence and maps post-translational modifications (PTMs) such as glycosylation, phosphorylation, oxidation, deamidation, and disulfide bonding. These attributes are considered critical quality attributes (CQAs) because they directly affect potency, pharmacokinetics, and immunogenicity.
Liquid chromatography-tandem mass spectrometry (LC-MS/MS) peptide mapping is the gold-standard method for primary structure analysis and a core capability within chemistry and compound analysis contract laboratories. Tryptic or multi-enzyme digestion generates peptide fragments separated chromatographically and detected by mass spectrometry, providing near-complete sequence coverage while simultaneously mapping sequence variants, modification sites, and PTMs. A certificate of analysis from a GMP-qualified contract lab formally documents the analytical procedures and acceptance criteria for each characterization parameter in the regulatory submission package.
MALDI-TOF mass spectrometry (matrix-assisted laser desorption/ionization time-of-flight) complements LC-MS/MS for intact mass determination and molecular weight confirmation of proteins and digestion products. N-terminal sequencing by Edman degradation confirms the first 20–30 amino acid residues and detects N-terminal truncations or signal peptide carry-over.
Key Primary Structure Methods at a Glance
| Method | Primary Use | Information Obtained |
|---|---|---|
| LC-MS/MS peptide mapping | Sequence confirmation, PTM mapping | Sequence coverage, modification sites, variants |
| MALDI-TOF MS | Intact mass / MW determination | Molecular weight, glycoform heterogeneity |
| Edman degradation | N-terminal sequencing | First 20–30 residues, signal peptide cleavage |
| Amino acid analysis (AAA) | Composition confirmation | Molar ratios of all amino acids |
| SDS-PAGE | Molecular weight, purity | Apparent MW, major impurity bands |
SDS-PAGE (sodium dodecyl sulfate-polyacrylamide gel electrophoresis) provides a rapid visual assessment of molecular weight and purity under denaturing conditions. It separates proteins by size after denaturation with SDS, enabling detection of fragments, aggregates, and co-purified impurities. Western blot testing extends SDS-PAGE by transferring separated proteins to a membrane and probing with an antibody to confirm identity and detect specific target proteins with high sensitivity.
Higher-Order Structure Analysis: Confirming Conformation
Higher-order structure (HOS) refers to secondary, tertiary, and quaternary protein organization, the folded three-dimensional conformation that determines biological function. ICH Q6B specifically requires HOS characterization as part of the structural characterization package for biopharmaceuticals.
Circular dichroism (CD) spectroscopy is the standard method for secondary structure assessment. Far-UV CD spectra report alpha-helix and beta-sheet content; near-UV CD probes the tertiary environment of aromatic residues. CD is widely used in biosimilar comparability studies to confirm structural similarity between an innovator and a proposed biosimilar product.
Hydrogen-deuterium exchange mass spectrometry (HDX-MS) maps solvent accessibility across the protein backbone at peptide-level resolution. It detects conformational differences, binding interfaces, and dynamic regions, making it a powerful orthogonal tool for biosimilar HOS comparability alongside CD and FTIR.
Fourier transform infrared (FTIR) spectroscopy, particularly attenuated total reflectance (ATR-FTIR), provides secondary structure content from the amide I band without requiring large sample volumes and is applicable to proteins in formulation matrices.
Dynamic light scattering (DLS) and size exclusion chromatography with multi-angle light scattering (SEC-MALS) characterize hydrodynamic radius, aggregation state, and oligomeric form in solution. Aggregation is a critical safety concern: protein aggregates can trigger immune responses that compromise both product safety and efficacy.
Biological Activity and Purity Characterization
Biological activity confirms that the protein retains its intended function. Enzyme-linked immunosorbent assay (ELISA) quantifies protein concentration and, in ligand-binding formats, measures binding affinity to a specific target. ELISA testing supports both identity confirmation and potency measurement within a single validated platform. For biopharmaceuticals, potency assays must reflect the product’s mechanism of action and are required under 21 CFR 610.10 as well as ICH Q6B, making them a central component of pharmacology and drug development testing programs.
Purity characterization addresses two categories of impurities: product-related (aggregates, fragments, charge variants, glycoforms) and process-related (HCPs, residual DNA, leachables from purification resins). HCP analysis by ELISA measures total residual host cell protein; LC-MS/MS-based HCP profiling identifies specific co-purified proteins that pose safety or stability risks, such as phospholipase B-like 2 (PLBL2), a CHO-derived HCP known to evade standard purification and to induce immunogenic responses in patients. Biopharmaceutical potency testing by contract laboratories covers both cell-based and binding assay formats, with validated methods designed to meet ICH Q6B and 21 CFR 610.10 requirements.
Isoelectric focusing (IEF) and capillary isoelectric focusing (cIEF) resolve charge variants arising from deamidation, C-terminal lysine clipping, and sialylation differences. Charge heterogeneity is a critical quality attribute for mAbs and Fc-fusion proteins because these variants can differ in pharmacokinetics and binding activity.
Glycan Analysis: A Critical PTM Category
Glycosylation is the most structurally complex PTM class and is directly regulated under ICH Q6B. N-linked glycans at conserved Fc sites govern complement activation, Fc receptor binding, and serum half-life. Glycan profiling by fluorescent HPLC after enzymatic release and labeling provides site-specific glycoform distribution. LC-MS glycopeptide analysis offers site-specific resolution with PTM context, confirming that glycosylation sites are occupied and identifying the specific glycan structures at each site.
For biosimilar programs, glycan similarity is a persistent FDA focus because manufacturing differences between cell lines frequently produce divergent glycoform profiles. Orthogonal glycan data, combining released glycan mapping with glycopeptide analysis, is expected in biosimilar BLA submissions.
Choosing a Contract Laboratory for Protein Characterization
Outsourcing protein characterization to a contract laboratory requires careful qualification. The most important considerations are regulatory compliance status (GMP, GLP, or GCP, depending on the development phase), instrumentation depth, method validation status, and experience with the specific molecule class.
Laboratories performing protein characterization for pharmaceutical clients must operate under ICH Q6B-aligned standard operating procedures, with validated analytical methods and calibrated instrumentation. ISO/IEC 17025 accreditation provides an independent verification of laboratory technical competence and is recognized by the FDA and EMA. Understanding the regulatory framework for biological products is essential before specifying analytical requirements for a contract lab engagement.
Key Questions When Qualifying a Contract Lab
| Consideration | What to Verify |
|---|---|
| Regulatory compliance | GMP/GLP qualification; 21 CFR Part 11 electronic records |
| Instrumentation | LC-MS/MS, MALDI-TOF, CD, FTIR, DLS, SEC-MALS on-site |
| Method validation | Validated vs. qualified assays; ability to transfer client methods |
| Experience | Relevant molecule class (mAb, enzyme, fusion protein, biosimilar) |
| Turnaround time | Routine vs. expedited capabilities; project management |
| Data package format | IND/BLA-ready reports; regulatory submission experience |
Contract Laboratory has facilitated characterization requests spanning FDA GMP and GLP environments, including HDX-MS programs, CD spectroscopy for biosimilar comparability, MALDI-TOF intact mass analysis, and SDS-PAGE/IEF for charge variant profiling. These requests come from pharmaceutical companies, academic researchers, government agencies, and biotech startups requiring regulatory-grade data packages. Stability studies are a downstream requirement once characterization confirms structural identity, since ICH Q1A-compliant studies demand stability-indicating analytical methods derived from the characterization package.
Emerging Approaches: Multi-Attribute Methods and AI-Assisted Analysis
Multi-attribute methods (MAMs) are increasingly adopted in biopharmaceutical quality control. MAMs use a single LC-MS/MS workflow to simultaneously monitor multiple CQAs, including sequence variants, PTMs, glycoforms, and process impurities, within one analytical run. The NIH-developed NISTmAb reference standard has been used extensively in interlaboratory studies to benchmark MAM performance across contract and internal labs, supporting method harmonization for regulatory submissions.
Computational tools, including AI-driven structure prediction (notably AlphaFold2 and its successors), now complement experimental characterization by predicting three-dimensional models from sequence. These predictions inform experimental design and support HOS interpretation, but they do not replace experimental data; FDA and ICH Q6B continue to require experimentally generated characterization datasets for regulatory submissions.
Taking the Next Step in Protein Characterization
Protein characterization is not a single assay but a coordinated analytical strategy aligned to the molecule’s complexity, the development phase, and the regulatory submission target. The methods selected, from primary structure peptide mapping through HOS analysis and glycan profiling, determine the quality and regulatory defensibility of the characterization package. Selecting a contract laboratory with the right instrumentation, compliance status, and experience in the relevant molecule class is as analytically important as choosing the methods themselves.
Need protein characterization testing? Submit a lab request to connect with and get quotes from industry experts.
This content includes text that has been generated with the assistance of AI. Contract Laboratory encourages the use of new tools and technologies that enhance our editorial process. Our full editorial policy can be found here.
Frequently Asked Questions
Protein characterization encompasses the analytical determination of a protein’s physical, chemical, and biological properties. This includes primary structure (amino acid sequence and PTMs), higher-order structure (secondary, tertiary, and quaternary conformation), purity, potency, and impurity profiling. For biopharmaceuticals, it covers all attributes defined as critical quality attributes under ICH Q6B.
ICH Q6B, Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products, is the primary harmonized guideline adopted by FDA, EMA, and other major agencies. It defines the scope of structural and functional characterization required to support new marketing applications for proteins and polypeptides from recombinant or non-recombinant cell-culture systems.
LC-MS/MS peptide mapping is the preferred method because it provides near-complete sequence coverage and simultaneously maps PTMs such as glycosylation, deamidation, oxidation, and disulfide bonds. It is typically supplemented with intact mass analysis by MALDI-TOF or LC-MS to confirm the whole-molecule mass and glycoform heterogeneity at the intact protein level.
Higher-order structure is characterized using a combination of orthogonal methods. Circular dichroism (CD) spectroscopy reports secondary structure content. HDX-MS maps backbone dynamics and solvent accessibility at peptide resolution. FTIR spectroscopy confirms secondary structure in formulated samples. SEC-MALS and DLS characterize solution-state oligomeric form and aggregation. No single technique is sufficient for HOS characterization in a regulatory submission.
The required compliance level depends on the development stage. Preclinical and early discovery programs may use GLP-qualified labs. Clinical phase characterization typically requires GMP-compliant operations with 21 CFR Part 11-compliant data systems. Biosimilar BLA submissions require validated analytical methods performed in GMP environments with full audit trails. ISO/IEC 17025 accreditation is a useful additional credential confirming technical competence.
Many full-service bioanalytical contract laboratories offer the core characterization suite, including LC-MS/MS, MALDI-TOF, CD, FTIR, DLS, SEC-MALS, and cell-based potency assays. Specialized techniques such as HDX-MS or cryo-EM may require specialist CROs. Complex biosimilar programs often engage multiple complementary laboratories to provide orthogonal data sets and reduce analytical risk concentration.